US-based biopharma company Dicerna Pharmaceuticals has appointed Bruce Peacock to its board of directors and audit committee.
He joins from Ophthotech where he served since 2010, most recently as its chief financial and business officer and prior to that, his previous roles include serving as chief operating officer of Cephalon and chief financial officer of Centocor.
Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Douglas Fambrough, CEO at Dicerna, said: “Bruce Peacock is a recognised leader in the biotech industry. With an impressive list of accomplishments in operations, management and business development, Bruce will be a terrific addition to our board.”